Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
21st Century Oncology Chooses Elekta for Replacement of Radiation Therapy Devices | ||
By: PR Newswire Association LLC. - 21 Nov 2017 | Back to overview list |
|
STOCKHOLM, Nov. 21, 2017 /PRNewswire/ -- Elekta (EKTA-B.ST) announces that 21st Century Oncology, the largest radiation oncology provider in the U.S., will replace several of its existing linear accelerators, as well as treatment planning software and oncology information systems, with advanced cancer treatment solutions from Elekta. The agreement includes Elekta's Versa HD™ linear accelerators, which combines high definition dynamic radiosurgery and precision radiation therapy treatments throughout the body in a single platform. It also includes Elekta's MOSAIQ® oncology information system – the Best in KLAS award winner – that enables optimization in health care practices through intelligent automation and actionable analytics. 21st Century Oncology will also upgrade to Monaco®, a state-of-the-art treatment planning solution that powers efficient high definition treatment planning with gold-standard accuracy. Gustavo Olivera, PhD, 21st Century Oncology's Chief Technology Officer, and Dr. Arie Dosoretz, a 21st Century Oncology member of the Office of the Chief Medical Officer, who oversees clinical operations, says: "Elekta's portfolio is well aligned with our strategic needs. Our partnership offers us a tremendous opportunity to update our domestic and international fleet of machines and continue to adapt our clinical offerings to an ever-evolving field. We are excited to implement our vision together now and in the years to come." Dr. Constantine Mantz, 21st Century Oncology's Chief Medical Officer, says: "Our ambition is to provide state-of-the-art radiation therapy. Upgrading to Elekta's innovative technology is as much an investment in our patients as it is in equipment. With this suite of solutions, we will be able to deliver high quality care for our patients in a highly efficient and integrated manner for our treatment centers." Peter Gaccione, EVP Region North America at Elekta, says: "We are very happy that 21st Century Oncology has chosen Elekta, a company that shares and supports their goal to offer the most advanced cancer treatment in a patient-centric setting focused on continuous innovation." USD 22 million has been booked in the second quarter of Elekta's fiscal year 2017/18. First deliveries of the new order are scheduled to begin in April, 2018, to centers in the USA. To learn more about these solutions, visit: For further information, please contact: Gert van Santen Tobias Bülow This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on November 21, 2017. (REGMAR) About Elekta This information was brought to you by Cision http://news.cision.com The following files are available for download: |
||
|
||
Copyright 2017 PR Newswire Association LLC. | Back to overview list |